Sangamo BioSciences traded at $4.59 this Wednesday July 6th, decreasing $0.08 or 1.71 percent since the previous trading session. Looking back, over the last four weeks, Sangamo BioSciences lost 14.18 percent. Over the last 12 months, its price fell by 57.81 percent. Looking ahead, we forecast Sangamo BioSciences to be priced at 4.16 by the end of this quarter and at 3.83 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Alnylam Pharmaceuticals 150.00 -0.73 -0.48% -13.09%
Amgen 245.25 -1.48 -0.60% 0.83%
Avrobio Inc 1.00 0.06 6.47% -88.09%
Bayer 56.19 0.67 1.21% 10.24%
BioCryst Pharmaceuticals 11.23 0.09 0.81% -29.33%
Biogen 215.98 3.40 1.60% -39.22%
Bluebird Bio 4.82 -0.23 -4.55% -84.51%
BioMarin Pharmaceutical 86.41 0.05 0.06% 4.06%
Gilead Sciences 62.73 0.39 0.63% -8.24%
GlaxoSmithKline 1,790.20 3.60 0.20% 24.58%
Intercept Pharmaceuticals 15.29 0.14 0.92% -19.44%
Ionis Pharmaceuticals 36.81 -1.04 -2.75% -5.52%
J&J 178.30 0.16 0.09% 5.25%
Karyopharm Therapeutics 5.22 -0.09 -1.69% -48.16%
Merck & Co 93.13 0.49 0.53% 18.55%
Novartis 81.22 0.31 0.38% -4.41%
Omeros 3.58 0.49 15.86% -75.56%
Pfizer 52.75 1.11 2.15% 34.05%
Ultragenyx Pharmaceutical 63.38 -0.42 -0.66% -29.29%
Regulus Therapeutics 2.07 0.06 2.99% 185.32%
Roche Holding 323.35 4.35 1.36% -9.16%
Sanofi 97.90 0.78 0.80% 12.79%
Sangamo BioSciences 4.59 -0.08 -1.71% -57.81%
Sarepta Therapeutics 75.97 0.23 0.30% 5.53%
Vertex Pharmaceuticals 291.16 2.18 0.75% 46.32%
Ziopharm Oncology 1.35 0.16 13.45% -45.12%

Indexes Price Day Year
USND 11362 39.61 0.35% -22.52%
US2000 1728 -13.78 -0.79% -23.32%

Sangamo BioSciences
Sangamo Therapeutics, Inc. is a clinical-stage genomic medicine company. The Company is focused on translating science into medicines that transform the lives of patients with serious diseases. Its product candidates include Giroctocogene fitelparvovec (SB-525), ST-920, SAR445136, ST-400 and TX200. Its SB-525, is a lead product candidate, a gene therapy for the treatment of hemophilia A. Its ST-920, is a gene therapy product candidate for the treatment of fabry disease. SAR445136, is its cell therapy product candidate for the treatment of sickle cell disease (SCD). Its ST-400 is a cell therapy product candidate for the treatment of transfusion dependent beta thalassemia. Its TX200, is a chimeric antigen receptor (CAR), engineered regulatory T cell (CAR-Treg), cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection.